These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20448367)

  • 1. [Research progress in aldose reductase].
    Gu J; Yan J; Wu W; Huang Q; Ouyang D
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 35(4):395-400. PubMed ID: 20448367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
    Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
    J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epalrestat improves diabetic wound healing via increased expression of nerve growth factor.
    Nakagaki O; Miyoshi H; Sawada T; Atsumi T; Kondo T; Atsumi T
    Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):84-9. PubMed ID: 23426701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
    Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
    Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
    Saraswat M; Muthenna P; Suryanarayana P; Petrash JM; Reddy GB
    Asia Pac J Clin Nutr; 2008; 17(4):558-65. PubMed ID: 19114390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
    No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldose reductase inhibitor ONO-2235 restores the alterations of bladder nerve growth factor and neurotrophin receptor p75 genetic expression in streptozotocin induced diabetic rats.
    Tong YC; Cheng JT
    J Urol; 2007 Nov; 178(5):2203-7. PubMed ID: 17870109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nerve flow dynamics in the pathogenesis of diabetic neuropathy].
    Ueda H
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():499-503. PubMed ID: 15999759
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of aldose reductase inhibitor on cutaneous nerve fiber length in diabetic patients.
    Yasuda H; Hirai A; Joko M; Terada M; Kawabata T; Maeda K; Haneda M; Kashiwagi A; Maeda T; Kikkawa R
    Diabetes Care; 2000 May; 23(5):705. PubMed ID: 10834436
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prevention and treatment of diabetic neuropathy].
    Uesaka Y
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():256-9. PubMed ID: 12430238
    [No Abstract]   [Full Text] [Related]  

  • 11. Purification and characterization of aldose reductase and aldehyde reductase from human kidney.
    Ansari NH; Bhatnagar A; Liu SQ; Srivastava SK
    Biochem Int; 1991 Nov; 25(4):755-65. PubMed ID: 1815509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA; Borja NL
    Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a new aldose reductase inhibitor on various tissues in vitro.
    Terashima H; Hama K; Yamamoto R; Tsuboshima M; Kikkawa R; Hatanaka I; Shigeta Y
    J Pharmacol Exp Ther; 1984 Apr; 229(1):226-30. PubMed ID: 6423811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients.
    Baba M; Kimura K; Suda T; Yagihashi S;
    J Peripher Nerv Syst; 2006 Jun; 11(2):176-8. PubMed ID: 16787519
    [No Abstract]   [Full Text] [Related]  

  • 15. Polyol formation and NADPH-dependent reductases in dog retinal capillary pericytes and endothelial cells.
    Sato S; Secchi EF; Lizak MJ; Fukase S; Ohta N; Murata M; Tsai JY; Kador PF
    Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):697-704. PubMed ID: 10067973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients.
    Kinekawa F; Kubo F; Matsuda K; Fujita Y; Kobayashi M; Funakoshi F; Uchida N; Watanabe S; Tomita T; Uchida Y; Kuriyama S
    Hepatogastroenterology; 2005; 52(62):471-4. PubMed ID: 15816460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldehyde reductase: the role of C-terminal residues in defining substrate and cofactor specificities.
    Rees-Milton KJ; Jia Z; Green NC; Bhatia M; El-Kabbani O; Flynn TG
    Arch Biochem Biophys; 1998 Jul; 355(2):137-44. PubMed ID: 9675019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldose reductase and its inhibition in the control of diabetic complications.
    Narayanan S
    Ann Clin Lab Sci; 1993; 23(2):148-58. PubMed ID: 8457142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE; Padiyara RS; D'Souza JJ
    J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progress on the drug therapy for diabetic microangiopathies: aldose reductase inhibitor].
    Hotta N
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():127-35. PubMed ID: 15999695
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.